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Residualizing labels for  protein, such as dilactitol- 
'261-tyramine (lZ6I-DLT)  and cellobiitol-'261-tyramine, 
have been used to  identify the tissue and  cellular  sites 
of catabolism of long-lived plasma proteins, such as 
albumin, immunoglobulins, and lipoproteins. The ra- 
dioactive degradation products formed from labeled 
proteins are relatively  large, hydrophilic, resistant  to 
lysosomal hydrolases, and accumulate in lysosomes in 
the cells involved in  degradation of the  carrier protein. 
However, the  gradual loss of the catabolites  from cells 
( tn  - 2 days) has limited the usefulness of residualizing 
labels in studies on longer lived proteins. We describe 
here a higher molecular weight (Mr - 5000), more 
efficient residualizing glycoconjugate label, inulin- 
'261-tyramine (lZ6I-InTn). Attachment of  "'1-InTn had 
no effect on the plasma half-life or tissue sites of catab- 
olism of asialofetuin,  fetuin, or rat serum albumin in 
the  rat. The  half-life  for  hepatic  retention of degrada- 
tion products  from '261-InTn-labeled asialofetuin  was 
5 days, compared to 2.3 days for '261-DLT-labeled 
asialofetuin. The whole  body half-lives  for  radioactiv- 
ity from '261-InTn-, "'1-DLT-, and '261-labeled rat 
serum albumin were 7.5, 4.3, and 2.2 days, respec- 
tively. The tissue distribution of degradation  products 
from '261-InTn-labeled proteins  agreed  with  results of 
previous studies using lZ6I-DLT, except that a greater 
fraction of total  degradation  products  was recovered 
in tissues. Kinetic analyses  indicated that  the  average 
half-life  for  retention of lZ6I-InTn  degradation  prod- 
ucts in tissues is -5 days  and suggested that in  vivo 
there  are both slow and rapid routes for release of 
degradation  products  from cells. Overall,  these  exper- 
iments  indicate that '261-InTn should provide greater 
sensitivity  and more accurate  quantitative  information 
on the  sites of catabolism of long-lived circulating pro- 
teins in  vivo. 
Residualking labels are biologically inert radioactive tags 
used for studies on the sites of protein catabolism in uiuo. 
These labels are designed to yield limit, hydrophilic degrada- 
tion products of a sufficient size that they are retained in 
lysosomes following catabolism of the carrier protein. The 
sites of degradation of the labeled. protein may then be deter- 
mined either by measuring acid-soluble radioactivity in var- 
ious tissues and cells or by autoradiography. Residualizing 
labels, such as [3H]raffin~~e (2), dilactitol-"51-tyramine (lZ5I- 
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DLT)' (3), and cellobiitol-"51-tyramine (4), have been used 
to identify the tissue  and cellular sites of catabolism of plasma 
proteins, such as albumin (5-7), lipoproteins (4, 8), and im- 
munoglobulins (9), and are also being increasingly used in 
studies on the uptake  and catabolism of proteins by cells in 
culture (8, 10). One of the limitations of the use of these 
labels, however, is that whereas their rate of loss from cells is 
slow ( t ~  - 2 days for '251-DLT in rat tissues), the rates of 
catabolism of plasma proteins  are often equally slow or slower. 
Thus,  a  substantial  fraction of degradation products is lost 
from tissues by the time significant amounts of the protein 
have been catabolized. Under these circumstances, it is not 
possible to assess rigorously the quantitative role of various 
tissues in catabolism of a protein since the distribution of 
degradation products  in the body could be biased by differ- 
ences in the rate of loss of the label from various cell types. 
Because of the limited residualization of tetrasaccharide 
derivatives of tyramine and the fact that residualization is 
improved with increasing saccharide content or molecular 
weight of the label (3), we set  out to design a higher molecular 
weight oligosaccharide derivative of tyramine, with the expec- 
tation  that  this label would be retained more efficiently in 
cells.  We describe here the biological properties of in~lin-"~I- 
tyramine ( lZ5I-InTn),  a residualizing glycoconjugate label de- 
rived from the inert  fructan polymer inulin ( M ,  - 5000). The 
retention of protein degradation products  containing the 1251- 
InTn label results from both  their size and  the absence of 
lysosomal fructofuranosidase activity (11). As shown below, 
lZ5I-InTn, the largest residualizing label for protein described 
thus  far, has negligible effects on the kinetics or  tissue  sites 
of plasma protein catabolism and is retained in lysosomes 
more efficiently than is lz5I-DLT. The  data indicate that lz5I- 
InTn should be  widely applicable in studies on the catabolism 
of long-lived circulating proteins. 
EXPERIMENTAL PROCEDURES AND RESULTS' 
The chemistry of synthesis and coupling of lZ5I-InTn to 
protein is outlined in Fig. 1 and described in detail under 
"Experimental Procedures." Also described in  the Miniprint 
are  a series of preliminary experiments validating the useful- 
ness of InTn  in studies on catabolism of circulating proteins 
such as asialofetuin and fetuin. The effectiveness of InTn as 
a residualizing label is clearly illustrated in Fig. 5, which 
shows both  the plasma and whole  body kinetics of clearance 
of Iz5I-, lz5I-DLT-, and "51-InTn-labeled RSA. Notably, as 
The abbreviations used are: lZ5I-DLT, dila~titol-~~~I-tyramine; lz5I- 
InTN,  in~lin-'~~I-tyrarnine; RSA, rat serum albumin; *I, lZ5I. 
* Portions of this paper (including "Experimental Procedures," part 
of "Results," Figs, 2-4 and 6, and Tables 1-111) are presented in 
miniprint at  the end of this paper. Miniprint is easily read with the 
aid of a  standard magnifying glass. Full size photocopies are included 
in the microfilm edition of the Journal that is available from Waverly 
Press. 
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FIG. 1. Reaction scheme for syn- 
thesis of lZSI-InTn and  its coupling 
to  protein. Inulin is reduced with 
NaBH4, and  the terminal alditol is oxi- 
dized with a limiting amount of periodate 
to generate an aldehyde. Tyramine is 
coupled to inulin aldehyde by reductive 
amination using NaBH3CN, yielding 
InTn.  InTn is then labeled with radio- 
active iodine using IODO-GEN and cou- 




with asialofetuin and  fetuin, the plasma half-life of RSA  was 
unaffected by the  attachment of InTn.  The  lZ5I-InTn degra- 
dation products also residualized more efficiently, with a 
whole  body half-life of about 7.5 days, compared to 4-5 days 
for lZ5I-DLT (Fig. 5 and Ref. 7). The tissue distribution of 
radioactivity at 4 days after injection of '251-InTn-labeled 
RSA, shown in Table 11, confirms previous evidence using 
lZ5I-DLT-labeled RSA that catabolism of RSA takes place 
primarily in muscle and  skin (7). However, in these experi- 
ments, a significantly greater fraction of total degradation 
products was retained in the body. Thus,  the circulating half- 
life of this  preparation of '251-InTn-labeled RSA  was 1.8 days, 
i.e. 79% catabolism at  4 days; the loss of 27% of radioactivity 
from the body by 4 days indicates that about 66% (2779) of 
the theoretical yield of '251-InTn-labeled RSA degradation 
products was recovered, compared to 45% for '"I-DLT-la- 
beled RSA (7). Overall, with all  three  proteins studied, the 
lZ5I-InTn label yielded results  consistent with previous studies 
using other labels, but with substantially improved retention 
of degradation products in the body. 
Kinetic Modeling of Plasma Protein Catabolism-As a  first 
step toward understanding the biological behavior of resi- 
dualizing labels, we have attempted to develop kinetic models 
for quantitative comparison of the rates of loss of the various 
labels from tissues. For  this purpose, we have used SCoP  and 
SCoPfit programs, which are simulation control and optimi- 
zation programs developed for the  IBM-PC/AT computer by 
the National Biomedical Simulation Resource at Duke Uni- 
versity (Durham,  NC).  SCoP generates a graphical simulation 
of a kinetic process, given a  series of differential equations 
(the kinetic model) and specified kinetic constants. The 
SCoPfit program accepts actual experimental data  and, using 
the SCoP model, develops kinetic constants  to optimize the 
I 
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fit of experimental data to the model. For the purpose of 
illustrating the results of calculations, experimental data from 
Fig. 5 (lower) are replotted in Fig. 7, showing the kinetics of 
whole body release of degradation products from lZ5I-DLT- 
labeled RSA (Fig. 7, upper) and '251-InTn-labeled RSA (Fig. 
7, lower). The various lines drawn on the graph represent 
different fits to  the  data using the SCoP  or  SCoPfit program 
with various models and assumptions, as described in detail 
in the Miniprint. In summary, the dotted lines are derived 
from the SCoP program using the three-compartment model 
described in Fig. 6 and assuming that RSA degradation prod- 
ucts leak from all tissues at  the same rate at which asialofetuin 
degradation products leak from liver. Because of the poor fit 
to  the experimental data, SCoPfit was used with the same 
model to optimize the kinetic constants  and  to improve the 
fit to  the data. However, this  SCoPfit optimization (dashed 
lines) was also unsatisfactory, and systematic error was ap- 
parent, suggesting that  the model was inappropriate. Since 
recent work  by Buktenica et al. (30) indicated that degradation 
products were routed through both slow and fast release 
compartments in cells in vitro, the three-compartment model 
was  revised to allow for a  fraction of degradation products to 
be released rapidly from cells in vivo. The solid lines in Fig. 7 
(upper and lower) are  the results of SCoPfit optimizations to 
this revised model and yield good and  consistent  fits to  the 
experimental data. The development, mathematical descrip- 
tion and assumptions, and the kinetic constants obtained 
with the various models are described in detail in the Mini- 
print. 
DISCUSSION 
The need for residualizing labels which are more completely 
retained in tissues has been apparent since the earliest exper- 
iments using this technology to identify the sites of plasma 
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FIG. 5. Kinetics of plasma and whole body clearance of 
radioactivity from RSA labeled with 1261, 1261-DLT, or IBI- 
InTn. Upper, kinetics of clearance of RSA from the circulation. 
Animals were injected with 10 X lo6 cprn (50-100 pg) of protein 
labeled with 1261 (0), I2'I-DLT (O), or lZ6I-InTn (A). Lower, kinetics 
of whole body clearance of RSA. Animals were injected with 2.5 X 
lo6 cpm of protein labeled with '''1 (0), Iz5I-DLT (O), or 12'I-InTn 
(A). 
protein catabolism. Because of the gradual loss of degradation 
products from tissues, it has been necessary to terminate 
experiments at times when only a  fraction of the protein  has 
been catabolized and then to apply corrections for intact 
protein remaining in tissues, for example, by acid precipita- 
tion of the  intact protein (3, 7) or by injection of a second, 
nonresidualizing tracer to estimate the amount of intact  pro- 
tein in the tissue (31). These manipulations are not only 
inconvenient, but they also ultimately affect the precision of 
estimates of protein degradation in tissues. Our previous work 
had revealed a  relationship between the number of carbohy- 
drate  units in the label and  its efficiency of residualization 
(3), so that the synthesis of a larger glycoconjugate label 
seemed a reasonable route for improving residualization. 
There  are obvious limits to  this approach, however, since at 
some point the size or  properties of the label itself will affect 
the mechanisms and sites of catabolism of the carrier  protein. 
An inulin derivative was chosen as  a reasonably sized target 
since the resulting molecular weight of the label would  be, at 
most, about 10% of the mass of the smallest plasma protein. 
The synthesis of InTn was straightforward, and  its iodination 
and coupling to protein proceeded with good efficiency, 30 
and 70%, respectively. Thus, only nanomolar quantities are 
required to label proteins with high specific radioactivity. The 
inertness of underivatized inulin  in the coupling reaction is 
also convenient because this inulin serves as a carrier to 
20 . +  
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FIG. 7. Results of kinetic modeling to  estimate rate of leak- 
age of various labels from cells. The data are replotted from Fig. 
5, bottom. The fitted lines are derived from equations described in 
text, and kinetic constants are listed in Table 111. 
decrease losses during handling, does not appear to interfere 
with labeling of the protein, and  is readily separated from 
labeled protein by  gel exclusion chromatography. In all of the 
experiments described here, the average substitution of pro- 
tein was limited to <1 mol of '261-InTn/mol of protein in 
order to decrease the probability of multiple derivatization of 
carrier proteins. The addition of 1 mol of 1261-InTn/mol of 
protein  had no detectable effect on the kinetics, mechanisms, 
or  sites of catabolism of asialofetuin, fetuin,  or RSA. This 
result  is  consistent with recent hypotheses on the regulation 
of protein catabolism. Thus,  the kinetics of protein catabolism 
appear to be determined by genetically encoded molecular 
features of the protein molecule, such as  the amino-terminal 
amino acid or a sequence or array of amino acids in the 
primary or  tertiary  structure of the protein,  rather than by 
bulk physical characteristics  such as hydrophobicity, subunit 
molecular weight, or isoelectric point (32). 
The size of the radioactive products isolated from urine 
using the [3H]raffinose (2), '261-DLT (3), or '261-InTN labels 
indicates that residualizing labels are excreted from the body 
largely in intact form. Thus, following catabolism of the 
carrier  protein, the labeled degradation products  appear to be 
released from cells by the process of exocytosis or regurgita- 
tion,  rather  than by deiodination or  eventual hydrolysis to 
lower molecular weight products. The difference in whole 
body half-life of radioactivity from asialofetuin labeled with 
raffinose, DLT,  InTn,  and other labels (3) indicates that  the 
structure of the label affects its  rate of release from cells. In 
addition, however, kinetic analysis indicates that  there  are 
also differences in  the routes of transport of these indigestible 
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compounds within the cell. Thus, whereas  some  residualiza- 
tion was  observed  with all of the labels,  there was a fraction 
of these labels  rapidly  released  from the body so that a 
significant lag  phase  in  whole  body  clearance  was not observed 
(Figs. 4 and 5, lower). Based on kinetic analysis, we have 
concluded that degradation  products  may be partitioned be- 
tween slow  and fast release  compartments within the cell and 
that routing of the partially  degraded  protein or labeled  deg- 
radation  products to the fast release  compartment may  be an 
important  factor limiting the long-term retention of  catabo- 
lites in the body. Our model makes no statement regarding 
the nature of the fast release compartment, although it is 
likely to be an early  endocytic  compartment, either prelyso- 
soma1 or in equilibrium with the lysosomal compartment. 
Whereas larger residualizing  labels  could theoretically prove 
more efficient, there is greater  risk that they will affect the 
catabolism  of the carrier  protein.  For most purposes, the InTn 
label should be suitable, for example, in studies on the catab- 
olism of IgGs, which are among the longest lived  circulating 
proteins ( tH = 3-5 days  in the  rat). 
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Inulin-1251-Tyramine, an Improved Residualiring Label for Studies an 
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Sites Of Catabolism of Circulating  Proteins 
EXPERIUENTAL  PROCEDURES 
W s i s  and Purification of I n  
to synthesis  and  iodination of InTn and coupling  of *I-lnTn to protein. 
: The  scheme in Fig. 1 shows Our route 
Inulin is generally described as a nan-reducing polysaccharide of 
fructose linked to a terminal sucr-o~e residue,  however most commercial 
preparations contain a fraction of incomplete chains with a redvcing 
frVCtOse  terminus ( 1 4 ) .  Sone enrichment for reducing inulin was obtained 
by fractionating inulin on Sephadex G-50  and pooling  the  fractions with 
highest ratio  Of  reducing sugar, measured by the  bicinchoninic acid array 
115). to total sugar, measured by the anthrone assay (16) (Fig. 211). 
using  fructose as standard  in  both assays. The  synthesis  of  InTn was 
the  procedure Of Raja et a l ,  (17) for reductive amination Of hyaluronic 
carried With the enriched inulin pool (Fig. 21). using an adaptation of 
acid with aliphatic amines. This procedure involves reduction of the 
terminal sugar Unit to an alditol,  followed by limited oxidation with 
periodate to generate a reactive aldehyde terminus, and reductive 
amination of the  polysaccharide  with  the amine. 
reducing  ends in the fractionated inulin preparation. For a typical InTn 
Reagent ratios in subsequent reactions are based on the Content of 
preparation,  inulin (12 mg total inulin/ml, 1.16 unole reducing sugar/ml) 
Vas dlSsolved in 0.1 POtllSS1Un borate, pH 8.3; oi 100-fold excess of 
solid  NaBH was added and the  solution  stirred  for 4 h at room temper- 
ature. Th% reaction vas quenched with 50 ul acetone, and 4 vo1umes of 
ice cold ethanol were added (final concentration B o t )  to precipitate 
inulin and ite derivatives. The solution was centrifuged in an IEC 
discarded and residual ethanol removed from the precipitate under a 
Centra  7R centrifuge  at 4 * C  for 10 lnin at 2500 rpm, the =upernatant 
stream Of nitrogen. The pellet was redi&rolved in 1.25 ml 30 mu imida- 
wle ,  pH 6.5, a I-fold excess O f  solid NaIO added and the mixture 
stlrred  at room temperature for 1 hl when a l l  the &iodate had been 
consumed. based on assay  for free periodate ( 1 8 ) .  The  periodate treated 
inulin was recovered Iollowing ethanol precipitation as above, 
immediately redissolved in 1.25 ml 0.1 U DOtassiUm borate. 7 . 7 5  and .~ 
an 8-fold excess of solid  tyramine added and the  BOlYtion Stirred at room 
temperature for 15  min  to allow Schiff-base formation: a 100-fold excess 
O f  NaBH CN was then added and reductive amination carrlad out overnight 
at room’tenperature with stirring. solid N ~ B H ~  (25:fold exceee) vas then 
added and the  mixture let stand for another  hour 1” order  to reduce any 
remaining  oxidized qroups. Inulin and derivatives were precipitated with 
ethanol and the  pellet di8601ved in 0.1 N NaC1 and chromatographed on 
Sephadex G-50 (Fig. 28). Fractions containing InTn (Fig. 28, fractions 
The  desalting  step also removed any residual free  tyramine  and  yieldea 
25-33) were pooled,  concentrated and desalted on Sephadex G-25 in n 0 
final InTn  preparation  containing -0.2 mol tyramine/mol inulin. 
~ . ~ ~ ~ .  ~~~ ”,
Labelins of Inulin and IT&. [3H1-inulin wan yepared by lduction Of 
fractionated inulin with 1 IO-fold excess of  NaB H as described above. 
of DLT and other residualizing labela ( 3 ) .  Typically InTn (lo m a l  
InTn was iodinated  using  methods described p r e v i d i y  for the iodination 
based on tyramine  absorbance at 220 nn) in 25 ul 0 . 5  N’potassiur. phor- 
phate, pH 7.7, was Placed in a 0.5 1 1  polypropylene centrifuge tube 
coated with 20 ug dried I d o g e n .  Na*I, 1 mci in 10 u1 0.1 N  NaOH 
added and the  iodination carried Out at room temperature for 20-30’m;:: 
The *I-InTn was isolated by cmntrifugal chroeatcqgrsphy on a 1 ml sephadex 
6-25  (Phamacla) column in water (2 min in an IEC u d e l  HN centrifuge at 
900 rpm). when an aliquot Of the *I-InTn was added to  carrier inulin (25 
ag/ml), > 8 5 t  at the  radioactivity was precipitable by 801 ethanol. The 
efficiency Of iodination Was about 301.  AS shown in Fig. 2C. +I-InTn 
radioactivity  eo-Chromatographed with total  carbohydrate (added carrier) 
On Sephadex G-50. 
Fou~lina of *I-InTn to D t&. The procedure for the coupling Of 
tyramine  derivatives to protein using Cycl is similar  to  that described 
previously ( 3 1 .  FOT a typical labeling, *l-ln~n, 10 ”mol in I5 UI 0.15 I 
Potassium  phosphate. pH 7.7, was placed in a 0 . 5  m1 polypropylene tube 
and activated by additxon of an equimolar amount Of Cycl in 4 u1 of 
acetone. After 30 SeS, protein. 2 mg (30-40  mol Of RSA or FET. 
respectively) in 50-200 ul PBS vas added with  wrtexing.  TO  estimate  the 
efficiency of coupling  to protein, a 1 u 1  aliquot Of the reaction mixture 
was removed after 5-10 min  and added to carrier  protein,  2 mg bovine 
serum albumin  (BSA) in 300 “1 H 0. then  precipitated  with an equal volume 
of 40% trichloroacetic acid (TcK). Efficiency of couplinq was 50-701 tor 
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the  various  protelns  tested. The *I-InTn-plOteln was Separated from free 
described previously (3). *l-lnTn-aeialofetUin (*I-InTn-ASF) was 
+I-InTn following dialysis and chromatography on Sephaicryl 5-200 as 
Prepared by treatment Of *I-InTn-FET (10 mg/m1 0.1 n Na acetate, pH 5.2) 
with one-half unit Of insolubilired neuraminidase far 4 h at 25 C. The 
desialylated protein vas re-isolated by Chromatography on Sephacryl S-200 
ments since ,958 of applied radioactivity was recovered in a single 
in PBS. NO protein polymers were detected in these labeling experi- 
Dmtein band on SDS-PAGE. 
Sprague-Dawley rats, 130-220 9. Methods for animal care and maintenance, 
In vivo Exosiments. Experiments were carried out in male and female 
iniection Of Droteins. and measurement Of ~ 1 a s m a  and whole bod" 
rahioastivity &e bee" described previously (irl). Unless etheruise 
indicated, a l l  data points for plasma and whale body clearance curves are 
averages for at least 3 animals and absence  of error bars indicates that 
the  coefficient  Of variation was 15%. Plasma Dind whole body half-lives 
were estimated by linear regression analysis. Total and acid Soluble 
radioactivity in tissues were distinguished by precipitation with 2 0 %  TCA 
as described previously (3,7). In control experlnent *I-InTn. *I-lnTn- 
PET or *I-InTn-RSA vas added to nonradioactive liver or skin, and 
processed for determination of acid Soluble radioactivity. Recoveries Of 
soluble radioactivity were 94-91) far .I-InTn. and 3.9% for *I-InTn-FET 
and *I-InTn-RSA. Subcellular fractionation of liver by differential 
centrifumation was nerformed accordinm t D  Crerroriadis aind Sourkes 1191. 
-2, Chromatographic  characterization Of inulin Dind derivatives. 
2h 1toDI: Chromatography Of natural inulin. Inulin (20 mg) was 
dissolved in 2 1 1  0.2 w NaCl and chromatographed on a Sephadex G-50 
column (1.5 x 47 Cn) in 0.2 M NDCI. Fractions. 2 ml. were collected and 
assayed for total I*) and  reducing (0) sugar as described  in  Haterials 
and Eethcds. Total sugar. measured as fructose, Was converted to m o l  
pooled for preparatlon  of InTn. 
inulin assuming Mr.- 5 , 0 0 0 .  Fractions 24-33 (bracketed in figure) were 
I
Of  tyramine to inulin aldehyde, the ethanol precipitate was dissolved in 
28 (middle): Chromatoqraphy  of an 1nTn reaction  mixture. After coupling 
0.2 M NaCl and chromatographed as above. Fractiona were assayed for 
total carbohydrate (0) and tyramine by absorbance at 220 nm (A). Frac- 
t i m a  19-21 (bracketed in flpre) were pooled for preparation of *I-InTn. 
-: Chromatographic profile of *I-InTn, prepared as described 
the  total  carbohydrata  profile ( a ) .  
I n  Materials and Hethods. Unlabeled  carrier inulin was added to obtain 
RESULTS 
-st- ~f Cou~linq 'I-InTn to  Proteb. One c~ncern about caupling 
residualiring  labels to protelnr in that  the  modificaeion Of the protein 
may affect the biological properties of the protein. To minimize 
structural  alterations in the  protein  the labeling reaction  is normally 
designed to yield (1 mol labrl/mol protein in order to decrease  the 
probability of modifying  the ..am protein molecule twice. with  the InTn 
by the 8 0 %  inulin carrier in the *I-InTn preparation. This seemed 
label  there was also the  possibility that  the  protein could be modified 
unlikely  because Of the  much higher pH required for reaction between 
cycl aind carbohydrates (22). but the  inertness of the  carrier inulin was 
also confirmed  experimentally. AS 6ho-n in Table I, CyCl  coupling of 
*f-I?Tn to 8SA proceeded  with an efficiency of 1 0 % .  compared to <I% for 
consistent with our previous  work indicating that CyCl couples  *I-DLT  to 
[ Hlmulln or in Control experiments without Cycl. The results are 
protein  via the  tyramine moiety (3). 
........................................................................ 
Table I 
Efficiency  of  couplinq of [3H]Inulln and *I-InTn to  proteln ........................................................................ 




[3H]lnulin  <1 
*I-Inulin-tyramine 7 0  
<I 
<I 
Prepared as dfrcribed in $laterials and nethods. Specific activi- 
ties Were 7.1 X 10 Cpm/nmol I Hllnulin  and 29 x IO6 cpm/nmol *I-InTn. 
The  specific radioactivity Of *I-InTn is based on its tyramine content, 
i . e . .  0.2 nmol tyraminelnmol  total inulin, thus IO nmol * ~ - l n ~ n  contains 
the  equivalent oi 50 n n o ~  total inulip. 
activated with 10 "mol CyC1, reacted with BSA (2 mq, 30 nmol in 200 "1 
Radioactive  Compounds (50 nmOl ( ")inulin and I D  nlOl *I-InTn) Were 
phosphate  buffer) and aliquots removed and assayed for acid preclpitable 
radioactivity as described in Materials  and nethods. 
c cycl was Omitted from control  experiments ........................................................................ 
m n i n a r v  N a l v e r i o n  Of  the 'X-XnTn -bel. ASF is used as FI model 
protein for evaluating residualiring labels because its kmetics Of 
clearance from the  circulation. its mechanism Of uDtake by heDatooYtes 
:a1 
Unlabeled ASF increased the  half-life Of *I-InTi-ASf to greater  than 0.5 
Of 
h, consistent  with  saturetion  Of  the  hepatocyte  receptor  for galaCtOBe- 
terminal  glycoproteins  and indicative that attachment of tI-InTn did not 
interfere  with clearance of ASP by this receptor-mediated pathway. In 
the  absence  of  competitor, more than 901 of injected radioactivitv from 
.I-I~T~-ASF was recovered  in  liver at 15 min  after  injection 
following injection Of labeled ASF. 
-. Kinetics of plasma and whole body clearance Of radioactivity 
injection of 2 mg unlabeled ASP. Animals were injected with 5 x 10' cpm 
a:Plasma clearance Of .I-IDTn-ASF and competition by EO- 
animals in each experiment. 
(-5ouq) of labeled protein. Data points are average values for 2 
3 8  lbottoml: Kinetics  Of  whale body clearance Of radioactivity from ASF 
animals were injected  with 2-3 x 10' cpm (t50 us) labeled protein. 
labeled with *I (0). *I-DLT l a )  0 *I-InTn (A). For each experiment 
animals were injected  with .I-InTn-ASF and sacrificed at 1 h, 1, I and 
In order  to  trace  the  disposition  of *I-lnTn metabolites in liver. 
'5 d. In a l l  cases >90% of hepatic  radioactivity Was in acid soluble 
recovered  in  the  liver at all times: stomach,  intestines  their  contents 
form. In addition, 92-95\ of radioactivity remaining in the body Was 
minimal  redistribution of the label into other tissues. Animals Yere 
accounted for a maximum of 2-3% of recovered radioactivity, indicating 
also  sacrificed  at 1 h, 1 and 3 d  after  injection, and livers removed 
and  fractionated  into nuclear mitoc~ondci.I-lys060~1  and  Supernatant 
fractions (19). The recovery'of radioactiYitY  in  these fr.CtiDnB Cor- 
responded to recovery of the lysosomal marker enzyme. beta-N-acetyl- 
hexosaminidase. In a11 cases, <IO1 Of radioactivity and enzyme activity 
were found in the post-lysosomal supernatant fraction, whereas when 
Intact *I-InTn-ASF was homogenized with liver and fractionated, 9 6 t  of 
the radioactivity. but only 12t of bet.-N-.cetylhexOs.minidaae activity, 
was recovered in the supernatant. In general. the results of these 
experiments With *I-InTn-ASF agreed Closely with Tflulte Obtained 
preVi4USly  with Other residualiring labels, such e.* ! w]raffinose (2) 
and *I-DLT (3). Thus, despite  its sire, the  attachment Of *I-InTn did 
not detectably  affect  the uptake. compartmentation or catabolism Of S F  
in liver. 
within 1 h, the 1065 Of radioactivity from the  whole body Yam used as oi 
Since *I-InTn-ASF was degraded to acid eolvble products in liver 
measure of the efficiency of residualization of the label. A comparison 
of the  whole body kinetics Of clearance of *I-ASF. *I-DLT-ASF and *I- 
InTn-ASF is Shown in Fig. 3 %  The residualization of the InTn label 
shows  about a 2-fold improvement over that Of DLT, with hali-lives Of 
2.3 and 5.1 d for the  *I-DLT and *I-InTn degradation products. respec- 
tively. The improvement in residualization  with *I-lnTn is con6i6tent 
with the relationship between molecular weight and efficiency Of 
residualization observed in our previous Dtudies 13). 
dies  With  Mna-liv& proteins. The *I-InTn label Was next applied t0 
%dies on the  catabolism of native fetuin. Fig. 4 shows  that  the whole 
body half-life  Of  radioactivity from *I-FET  is about 1 d,  which itr equal 
+n its nlacna half-life in the r a t  1 2 4 ) .  while  the  whole bod" half-lives _ _  ."  ."" ..~" "" ". ~~ ~ ~~~ 
were 3-3.5 and 5-6 d for *I-DLT-FE< bid *I-InTn-FET, rerp;ctively. in 
several experiments. The tissue distribution of radioactivity was 
determined. as described  in  Haterials  and nethod-. at 2 d  (2 half-lives1 
after  injection of *I-DLT-FET and *I-InTn-FET. The overclll distribution 
majority Of  degradation product- being  recovered in muscle and 3kin, in 
of  radioactlvlty was similar in both cases (data  not shown), with  the 














=with *I ( 0 ) .  '1-DLT (e )  or *I-InTn (A). Animals were injected 
. Kinetics  of  whole body clearance of radioactivity from fetuin 
with 2.5 x 10' Epm (25-50 Y9) of labeled  protein. 
The  tissue  distribution Of radioactivity at 4 d  after injlction Of 
*I-InTn-MA.  shown in Table 11, confirms  previous  evidence  using *I-DLT- 
RSA that  catabolism of RSA taker  place primarily in muscle and s k i n  (11 .  
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Table I1 
Recovery Of radioactivity and distributlon  of  degradation  products in 
tissue.. 4 days  after  injectLon of * I - I ~ T ~ - R S A  m ratsa 
Tissue  \cpm recoy red i acid-soluble  tprotein 
""__..""_".""""""".."""..""""."""."""""""" 
in body' 
37.8 * 2.9 
radioactivity catabolized' 
Skln 
nuscle 30.9 * 1.7 
."""""""""""""""".."""."""""""".."""""" 
67.8 z 4.9 25.6 
51.9 * 4.e 16.0 




Spleen 0 . 8  0.2 
2.1 * 0.2 
10.4 * 6.6 
14.9 1.4 







9.8 1.5 <I 
Total and acid soluble radioactivity in tissues were measured as 
a Animals were injected with 12 x lo6 cpm (-100 "91 'I-InTn-RSA. 
desc ibed in laterials and nethods. E Data are expressed as means and Standard deviationr for three 
animals.  Recovery of radioactivity in the bady at 4 days was 73 1 1 
Of in~ected dose. The sum Of radioactivity recovered in tissue5 and 
excreta accounted  for 91 t 5 t of injected dose. I&== than 1% of total 
bone.cand stomach and intestine and their contents. 
radioactivity vas recovered in toto in heart. lung. thymus. thyroid, 
Percent protein catabolized was determined by multiplylng the 
average i recovered dose (CO~UIPII 2) by the average I acid-soluble 
radioactivity (Column 3 )  for each tissue. 
"_....""""..""""""""""""".""""""""""-"""- 
xinetis  ModelinD  of P1 
6 was chosen as the  Simplest  three compartrnent model  for  describing  the 
a s m  P otein  Cbtabolisn.  The  model  shown in Fig. 
pathway Of catabolism Of plasm proteins. This  model  treats a11 extrs- 
cellular  protein as a single pool and assme5 that  the  distribution  Of 
the  protein  between vascular and extravascular  compartments  exerts an 
assumption  is supported by the ObfeNation  that  the kinetics of Whole- 
insignlficant effect on its fractional catabolic rate (FCR). This 
body elimination of radioactivity from *I-FET and *I-RSA (Figures 4 and 
58) are linear from time  of  injection  and  extrapolate  to essentially 
1008 af injected dose at zero time. The FCR (k ) for these  proteins can 
be estimated from the  slooe Of either  the Yhole'bodY clearance Curve for 
*I-labeled protein or the  linear  phase Of the  pldsma Clearance Curves 
using any of the labels: the  two  methods yield identical reCYltS, i.e., 
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EXCRETA 
disposition of  degradation products. 
w. Basic kinetic model for CataboliSm of plasm proteins  and 
model in Fig. 6 are Straightfomdrd: 
The  differential  equations used in the  SCoP program to define  the 
(11 d(PLl/dt = -kl*(PLl. 
(2) dC/dt I kl*(PL) - k3*C,  and 
( 3 )  dE/dt = k *C: 
where  PL = intact  tracer in the ex&acellular (plasma + lymph) space. 
C - labeled  catabolites in the  intracellular  compartment, and 
E = labeled  catabolites in excreta. 
The  Constants  k and k ore not used in the  calculations for the  model 
since. based kn ?2uperim!bts with  ASF (Fig. 3 1 ,  the  rates Of dearadation 
the  actual data POibts, but a more fundamental error is  oppaGent insofar 
as the  shape  of  the curves does not fit the  actual  trend in the data. 
similar  results  (graphs not shown) Were obtained with  data on whale body 
clearance Of *I-DLT-FET and *I-InTn-FET. using a k1 ,value of 0.59, 
estimated from the  actual  half-life Of *I-FET. as shown m Fig. 4. 
As an alternative  approach to fitting the  data, it was accepted 
model for predicting  the half-life of degradation  prOdUCtS in peripheral 
that release Of  ASF  degradation  products from liver  might not be a good 
tiBsUe6. Thus. the SCoPfit program was used to obtained Optimized 
values of and k3.  The  FCR  for RSA (kll was assigned an initial value 
of 0.31 d-f? with D range of 0.31-0.39 d , >.e., a half-life of 
1.8-2.2  d. the  observed range for the  half-life of RSA in our laboratory 
P17,25 and Fig. 5). Initial values chosen  for k were 0.30 and 0.136 
for 'I-DLT and *I-InTn, respectively. estikated as above from 
studies  with *I-DLT- SF  and *I-InTn-ASF (Fig. 3);  the  allowed range for 
k was 0.01-0.99 d-'. The dashed lines in Fig. 1 show  the  calculated 
bist fit to the  data,  Obtained using the RUnge-Kutta integrator  routine 
deviatim from the experimental data, consistently Overshooting the 
in the  SCoPfit program. Both of these  lines also reveal a systematic 
experimental data point5 at early timer and undershooting at later 
times. A s  in the DrevioUS analvsis u d n a  SCoP. similar discremancies 
and systematic er&rs Yere obtdined on optimizations with da<a from 
experiments with *I-DLT-FET and *I-InTn-PET (graphs not shown). The 
resulting  kinetic  COnStants for the  Optimilationr  with  both  the RSR and 
the poor fit to  the  data,  the optimized values Of  k are Of concern 
FET data are summarized in Table 111 (Original nodel). In  addition  to 
degradation  products fram the body (0.9-1.0 and 2.2-2.6  d. respectively) 
since the corresponding half-lives for loas Of *I%LT and *I-InTn 
are short, conpared to Observed differences in residualiration Of 
degradation products from 'I-. *I-DLT- and +I-InTn-labeled proteins 




RSF *I-DLT <0.01 0.31 2.3 
*I-lnTn <0.01 0.136 5 . 1  
"". "". """ ""_ ."" "". """ . .  
 
FET  *I-DLT 0 . 5 8  0.74 0 . 9 1  0.31 53 L , . 2 9  2.5 
*I-InTn 0.58 0.32 2.2 0.43 13 0.17 4 . 3  
RSA *I-DLT 0.31 0.70 1.0 0.12 3 8  0.21 1.0 
+I-InTn 0.31 0.21 2.6 0.24 77 0.16 4.3 
................................................. 
described in tert. allows  for partitloninq Of degradation  products into 
a original Model is described in Fig. 6. Compartmental nodel. 
fast and slow release comoartments. 
The cons rant^ ~ is'equivalent to  the FCR of the protein. 
the kinetics Of reyeas. of degradation products 
The constan;, '&' and the corresponding half-lifef;za2) refer  to 
det mined experimentally for ASF and by SCoPfit f o r  FET and RSA. 
cells, as 
slow release compartment: klr is. one component of  the  total FCR. 
' The  ConSLant.  LIS,  refers  to  the rate of uptake of protein into the 
the ?I& release compartment. It is  determined as: Fs = kl,/k 
e F  represents  the percent Of total protein catabolism  shunted into 
kinetics of 
The  Constant reledsek3gi and the corresponding half-lzfe re&; to  the 
degradation DrOduCts from the slow-release 
compartment. a16 determined by SCoPfit optimization. 
..""""___..""""".."""".."""""""""""""""""~ 
correlate well with exnerimental data. SumestinQ that the three- 
Overa l l .  the fitted curves generated in the above analyses do not 
Thus,  while  the kinet<cs Of release Of degradation  products from the 
bod" are  oseudo-first  order in "1 dose  renainina" rFi7s. 4 and 581, the 
seGent1.i model  predicts some initial period during .which radiobstive 
degradation  products  should  aCCUmulate in the  intracellulbr compartment. 
Thus. as observed with both  the dotted and dashed lines obtained in the 
degradation  products from the body while. In fact. however,  the data 
previous analyses, there should be a lag phase in the release Of 
plot) to 100% of dose at zero time. while there is only a slight 
for *I-DLT-RSA and *I-DLT-FET extrapolate nearly linearly (on e. semi-log 
indication  of a IaQ-Dhase for release of *I-InTn-FET  and *I-IDTn-RSA 
praducte (Figs. 4 ,  58 and 7 ) .  One po96ible explanation for this 
discrepancy  is  that  residualiring labels are not retained efficiently by 
with minrmal kinetic delay. This was considered unlikely, however. 
a11 cell types. and  that some cells nay release degradation products 
because  non-degradable  compounds are known  to  residualire well in a11 
, .  
cell types which have been Studied thus far in vivo and in vitro. 
Relevant studies in vivo include those demonstrating retention of 
residualizing  labels in hepatocytes using ASF as. carrier protein (2.3.24 
denatured  albumin ( 2 . 2 4 1 ,  skin and muscle fibroblasts  using RSA (11 and 
and Fig 4 1 ,  hepatic non-parenchymal cells using RNase 8 and heat- 
vitro have shown  that residualizing labels are retained  efflciently in 
aortic endothelial using lipoproteins (26). In addition, studies in 
fibroblasts (8.10) and in cardiac endothelial cell5 (unpublished 
observationrl. Finally. numerous studies have shown  that "on-demradable 
compounds, including &rose 127,281. cellobiose and ficoll (21) and 
poly-D-amino acids (29) accumulate in macrophage 1ysosr)mes in vitro. 
The Widespread pathology associated rlth various lysosomal storage 
diseases also suggests that at least tkmporary accumulation of non- 
degradable  materials is Characteristic of cellular metabolism. 
A  Dossible  exolanatlon for Door fit between between nodel and data 
was sudgested by 'recent studies of Buktenica et al. (30) Who have 
proposed that proteins token into cells by fluid-phase endocytosis, 
along with  their  degradation products, may be excreted from cells by two 
distinct pathways, i.e. from rapid and slow release Compartments. In 
their  Studies  they  demonstrated  that a fraction Of degradation products 
from *I-labeled proteins were released from cells lmouse Deritoneal 
macrophages and biby hamster kidney fibroblasts1 with a half-life Of 
compartment and released With a half-life Of 1-2 d in vitro. These 
5-10 mi", while  another fraction was apparently trapped in a ly6060mal 
Obse-ations suggested to us that degradation products containing 
residualizing  labels  night also be partitioned in cells in vivo. One 
fraction might be released rapidly, explaining the absence Of a lag 
phase 1" release of degradatlon products from the body. and another 
fraction retained and reletsed slowly from the lysosonal compartment. 
a11 endocytosed proteins.  and that differential  residualiration would 
It can then be postulated  that both of  these  routes are accessible  to 
result from differences in partitioning Of the degradation products 
between  the  two pathways. 
modified to a compartmental  model which allowed for rapid release of a 
As a test  of  this hypothesis. the Original model (Fig. 61 was 
model for RSA were modified as follows: 
fraction Of degradation products from cells. The equations for the 
(1) d(PL)/dt = -klt*(PL), 
(2) dC/dt = kl5*(PL) - k3**C, and 
(3) dE/dt = kls*C + klf*(PL): 
where  kit is the  total FCR for RSA (0.31 d - l l ,  k and klf represent the 
fraction of total FCR occurring via  the blow- ah8 fast-release Empart- 
from experiments with both *I-DLT-RSA and *I-InTn-RSA. Equally good 
FET and *I-InTn-FET (Fig. 4 ) .  substituting  the constant. 0.59 d-l for 
fits  (graphs  not  shown) were obtained for the  experiments  with *I-DLT- 
products released v i a  the slow-release compartment and the kinetic 
0.11 d-l In the shove equations. The estimated percent Of  degradation 
Constant* 
reridualiling*3siabJnsd Obtained from  the several experiments Were 
Corresponding half-lives for retention  of 
degradation prxluotr shunted into the slaw release compartment 
internally consistent and reasonable.  Thus,  the  the  fraction of 
Table 111. Col. 7) increases from 38-53% for *I-DLT-labeled FET and(& 
to 73-77% for the *I-lnTn-labeled prateins. Consistent  with incraased 
efficiency Of residualiration  Of *I-InTn-labeled degradation products. 
In addition. the values of kIS estimated with  FET and RSI\ for *I-DLT and 
*I-InTn degradation  products  are 2.5-3.0 and 4.3 d. respectively  (Table 
111, Co1. 91 and are in reasonable agreement with  the 2.3 and 5 . 1  d 
half-lives Observed for ASF degradation  products  in  liver  (Table 111, 
Col. 4 ,  and Fig. 1). While  this  model  represents a11 cells involved in 
the  Catabolism Of RSA or FET as a Single  compartment and as8ume9 that 
the  distribution Of degradation  products between slow and fast release 
compartments and their  rates  Of  transport hrough the cell are identical 
for all cell types. there  is not a sufficient  amount Of experimental 
data with  various  proteins and labels to justify a more eophistisatsd 
treatment at this time. However, the internal consistency  and reason- 
ableness Of the  Linetic  constants obtalned from the optimization. as 
well as the  quality Of the fit to experimental data for  both  FET and 
RSA, lend some support  to  the  compartmental model and  justify continued 
experimentation to test  the  model in vivo  and i n  simpler  model  systems 
in vitro. 
